InnoCare Pharma, kambani inotungamira biopharmaceutical, yazivisa nhasi kuti murwere wekutanga akaiswa muchikamu chechipiri chekiriniki yeBruton's tyrosine kinase (BTK) inhibitor orelabrutinib kurapwa kwekutanga immune thrombocytopenia (ITP) kuChina.
Primary immune thrombocytopenia (ITP), inonziwo idiopathic thrombocytopenic purpura, chirwere chinowanikwa chekudzivirira zvirwere chinoratidzwa nekudzikira kwehuwandu hweplatelet yeropa, zvichikonzera kuwedzera kwenjodzi yekupwanya uye kubuda ropa[i]. Iyo huru pathogenesis yeITP kurasikirwa kwekudzivirira kwemuviri kune platelet auto-antigens. Uku kusashivirira kwekudzivirira kwemuviri kunotungamirira kukuparadzwa kweplatelet uye kuderera kwekugadzirwa kweplatelet kubva ku megakaryocytes ne autoantibodies uye cytotoxic T lymphocytes.
Vanenge 70% chete varwere vanopindura kurapwa kwekutanga, vamwe varwere vachiri kuramba kana kudzoka shure mushure mekurapa kwakasanganiswa, saka zvinodikanwa kuongorora zvinangwa zvekurapa zvitsva. Inhibition yeBTK inogona kuderedza kuparadzwa kweplatelet nekudzivisa B cell activation uye autoantibody kugadzirwa.
Chiitiko chegore negore cheITP muvakuru chingangoita 2-10 nyaya itsva pa100,000 vanhu[ii],[iii]. Vakwegura vanopfuura makore makumi matanhatu vari panjodzi huru yeITP, uye vanhukadzi vekuzvara vane njodzi huru kupfuura varume vezera rimwe chete.
Dr. Jasmine Cui, mubatanidzwa, Chairwoman uye CEO weInnoCare akati, "Hapana BTK inhibitor yakabvumirwa kurapwa kwevarwere vane ITP munyika. BTK ndiyo kiyi kinase muB cell receptor signing pathway, iyo yakakosha pakushandiswa kweB lymphocytes, macrophages uye mamwe masero edziviriro pamwe nekugadzirwa kwemasoja ekudzivirira chirwere mupathological process yeITP. Orelabrutinib ine yakakwira tarisiro yekusarudzika ine nhoroondo yekuchengetedza, iyo inotarisirwa kuunza nzira dzekurapa dzinoverengeka kuvarwere veITP. "
ZVOKUBVA MUNYAYA INO:
- BTK ndiyo kiyi kinase muB cell receptor signing pathway, iyo yakakosha pakushandiswa kweB lymphocytes, macrophages uye mamwe masero edziviriro pamwe nekugadzirwa kwemasoja ekudzivirira chirwere mupathological process yeITP.
- Primary immune thrombocytopenia (ITP), inonziwo idiopathic thrombocytopenic purpura, chirwere chinowanikwa chekudzivirira muviri chinoratidzwa nekudzikira kwehuwandu hwemaplatelet eropa, zvichikonzera kuwedzera kwenjodzi yekupwanya uye kubuda ropa[i].
- Jasmine Cui, co-muvambi, Chairwoman uye CEO weInnoCare akati, "Hapana BTK inhibitor yakabvumidzwa kurapwa kwevarwere vane ITP munyika.
